Oncology Voice Network
Join to access to all OVN content. Join for Free
What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms
Amplify Consulting Services field medical teams pharma leadership medical value proposition biotech industry insights

What's Next: Co-creating the next reality for Field Medical after a crisis with Craig Simms

  • Apr 28th 2020
  • 40 mins
  • E6

Share This Article

Summary

Today I have Craig Simms, CEO of Amplify Consulting Services and Former MSL Director of Astellas Pharma. Our topic for today is What’s Next: Co-creating the next reality for field medical teams following a global crisis. Really interesting topic, you’re going to enjoy it.

Key Points

  • What Craig is hearing from leaders in pharma, biotech, and medical device companies right now
  • Framework and powerful questions
  • Staying medically relevant, creating value, and value proposition
  • Advice to medical affair leaders in handling moral issues and getting people back to work (once the crisis is over)

Click for Source
Amplify Consulting Services, field medical teams, pharma leadership, medical value proposition, biotech industry insights

Related Topics

See More Topics

Meet Our Innovation Partners

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23rd • 8 mins • read
Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Feb 22nd • 10 mins • read
Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Feb 11th • 4 mins • read
Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Sep 3rd • 1 min • read
Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 9th • 5 mins • read
Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Dec 2nd • 2 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN